ЭВОЛЮЦИЯ ЛЕЧЕНИЯ РАКА ТЕЛА МАТКИ
Abstract
Статья посвящена эволюции хирургического, лучевого и лекарственного лечения рака тела матки на протяжении последних 20 лет. В ней обсуждаются результаты ключевых исследований по данной проблеме, изменившие подходы к лечению этой патологии.
About the Authors
V. M. Nechushkina
Российский онкологический научный центр им. Н. Н. Блохина
Russian Federation
Russian Federation
K. Yu. Morkhov
Российский онкологический научный центр им. Н. Н. Блохина
Russian Federation
Russian Federation
V. V. Kuznetsov
Российский онкологический научный центр им. Н. Н. Блохина
Russian Federation
Russian Federation
References
1. Boronow, R. C. Endometrial cancer: not a benign disease / R. C. Boronow // Obstet. Gynecol.– 1976.– Vol. 47, N5.– P. 630–634.
2. Childers, J. M. Combined laparoscopic and vaginal surgery for the management of two cases of stage I endometrial cancer / J. M. Childers, E. A. Surwit // Gynecol. Oncol.– 1992.– Vol. 45, N1.– P. 46–51.
3. Cost and quality-of-life analyses of surgery for early endometrial cancer: laparotomy versus laparoscopy / N. M. Spirtos, J. B. Schlaerth, G. M. Gross et al. // Am. J. Obstet. Gynecol.– 1996.– Vol. 174, N6.– P. 1795–1799.
4. Lymph node yield from laparoscopic lymphadenectomy in cervical cancer: a comparative study / J. M. Fowler, J. R. Carter, J. W. Carlson et al. // Gynecol. Oncol.– 1993.– Vol. 51, N2.–P. 187–192.
5. Phase III trial of laparoscopy versus laparotomy for surgical resection and comprehensive surgical staging of uterine cancer: a Gynecologic Oncology Group study / J. Walker, R. Mannel, M. Piedmonte et al. // Gynecol. Oncol.– 2006.– Vol. 101 (suppl. 1).– P. 11–12.
6. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study / J. Walker, M. Piedmonte, N. Spirtos et al. // J. Clin. Oncol.– 2012.– Vol. 30, N7.– P. 695–700.
7. Бохман, Я. В. Метастазы рака матки / Я. В. Бохман.– Л.: Медицина, 1976.– 159 с.
8. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study / W. T. Creasman, C. P. Morrow, B. N. Bundy et al. // Cancer.– 1987.– Vol. 60, N8 (suppl.).– P. 2035–2041.
9. Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients / J. K. Chan, R. Urban, M. K. Cheung et al. // Cancer.– 2007.– Vol. 109, N12.– P. 2454–2460.
10. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study / ASTEC study group, Kitchener H., Swart A. M. et al. // Lancet.– 2009.– Vol. 373, N9658.– P. 125–136.
11. Creasman, W. T. The current status of lymphadenectomy in the management of endometrial cancer / W. T. Creasman // Womens Health (Lond. Engl).– 2011.– Vol. 7, N1.– P. 33–35.
12. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis // Y. Todo, H. Kato, M. Kaneuchi et al. // Lancet.– 2010.– Vol. 375, N9721.– P. 1165–1172.
13. Therapeutic impact of para-aortic lymphadenectomy in patients with high-risk, early stage and advanced stage endometrial carcinoma / Y. Suzuki, Y. Todo, K. Okamoto et al. // Proceedings of the 13th Biennial Meeting of International Gynecologic Cancer Society, Prague, 23–26 Oct 2010.– Abs. 1433.
14. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial / P. Benedetti Panici, S. Basile, F. Maneschi et al. // J. Natl. Cancer Inst.– 2008.– Vol. 100, N23.– P. 1707–1716.
15. The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer / J. P. Chino, E. Jones, A. Berchuk et al. // Int. J. Radiat. Oncol. Biol. Phys.– 2012.– Vol. 82, N5.– P. 1872–1879.
16. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up / N. Colombo, C. Creutzberg, F. Amant et al. // Radiother. Oncol.– 2015.– Vol. 117, N3.– P. 559–581.
17. Amant, F. Cancer of the corpus uteri / F. Amant, M. R. Mirza, C. L. Creutzberg // Int. J. Gynaecol. Obstet.– 2012.– Vol. 119, Suppl. 2.– P. S110—S117.
18. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer / L. J. Havrilesky, J. Cragun, B. Calingaert et al. // Gynecol. Oncol.– 2005.– Vol. 99, N3.– P. 689–695.
19. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer / J. M. Cragun, L. J. Havrilesky, B. Calingaert et al. // J. Clin. Oncol.– 2005.– Vol. 23, N16.– P. 3668–3675.
20. Pelvic lymphadenectomy in the surgical treatment of endometrial cancer / F. Girardi, E. Petru, M. Heydarfadai et al. // Gynecol. Oncol.– 1993.– Vol. 49, N2.– P. 177–180.
21. Corpus: epithelial tumors / D. S. McMeekin, C. Yashar, S. Campos, R. J. Zaino // Principles and Practice of Gynecologic Oncology / R. R. Barakat, A. Berchuk, M. Markman, M. E. Randall (eds.).– 6th ed.– [S. l.]: Wolters Kluwer / Lippincott Williams & Wilkins, 2013.– P. 661–714.
22. Surgery and postoperative radiotherapy versus surgery alone for patients with stage 1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. PostOperative Radiation Therapy in Endometrial Carcinoma / C. L. Creutzberg, W. L. van Putten, P. C. Koper et al. // Lancet.– 2000.– Vol. 355.– P. 1404–1411.
23. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study / H. M. Keys, J. A. Roberts, V. L. Brunetto et al. // Gynecol. Oncol.– 2004.– Vol. 92, N3.– P. 744–751.
24. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis / ASTEC/EN.5 Study Group, P. Blake, A. M. Swart et al. // Lancet.– 2009.– Vol. 373, N9658.– P. 137–146.
25. Johnson N., Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis // BJOG.– 2007.– Vol. 114, N11.– P. 1313–1320.
26. Long-term outcomes after pelvic radiation for early-stage endometrial cancer / M. Onsrud, M. Cvancarova, T. P. Hellebust et al. // J. Clin. Oncol.– 2013.– Vol. 31, N31.– P. 3951–3956.
27. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients / J. Aalders, V. Abeler, P. Kolstad, M. Onsrud // Obstet. Gynecol.– 1980.– Vol. 56, N4.– P. 419–427.
28. Адъювантная дистанционная лучевая терапия при раке тела матки I – II стадий / В. М. Нечушкина, К. Ю. Морхов, В. В. Кузнецов, А. В. Егорова // Онкогинекология.– 2014.– № 4.– С. 37–44.
29. Нечушкина, В. М. Рак тела матки (факторы прогноза и тактика лечения): дис. … д-ра мед. наук: 14.01.12 / Нечушкина Валентина Михайловна.– М., 2013.– 445 с.
30. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis / A. Kong, N. Johnson, H. C. Kitchener, T. A. Lawrie // J. Natl. Cancer Inst.– 2012.– Vol. 104, N21.– P. 1625–1634.
31. Comparison of clinical and surgical staging in patients with endometrial carcinoma / T. A. Cowles, J. F. Magrina, B. J. Masterson, C. V. Capen // Obstet. Gynecol.– 1985.– Vol. 66, N3.– P. 413–416.
32. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study / R. C. Boronow, C. P. Morrow, W. T. Creasman et al. // Obstet. Gynecol.– 1984.– Vol. 63, N6.– P. 825–832.
33. Tumor size in endometrial cancer: a prognostic factor for lymph node metastasis / J. C. Schink, J. R. Lurain, C. B. Wallemark, J. S. Chmiel // Obstet. Gynecol.– 1987.– Vol. 70, N2.– P. 216–219.
34. Conservative management of stage I endometrial carcinoma after surgical staging / J. M. Straughn, Jr., W. K. Huh, F. J. Kelly et al. // Gynecol. Oncol.– 2002.– Vol. 84, N2.– P. 194–200.
35. Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy / J. M. Straughn, W. K. Huh, J. W. Orr, Jr. et al. // Gynecol. Oncol.– 2003.– Vol. 89, N2.– P. 295–300.
36. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial / R. A. Nout, V. T. H. B. M. Smit, H. Putter et al. // Lancet.– 2010.– Vol. 375, N9717.– P. 816–823.
37. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial / R. Maggi, A. Lissoni, F. Spina et al. // Br. J. Cancer.– 2006.– Vol. 95, N3.– P. 266–271.
38. Randomized phase III trial of pelvic radiotherapy versus cisplatin- based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study / N. Susumu, S. Sagae, Y. Udagawa et al. // Gynecol. Oncol.– 2008.– Vol. 108, N1.– P. 226–233.
39. Randomized phase III trial of WART versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a GOG study / M. Randall, V. Filiaci, H. Muss et al. // J. Clin. Oncol.– 2006.– Vol. 24, N1.– P. 36–44.
40. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study / G. F. Fleming, V. L. Filiaci, R. C. Bentley et al. // Ann. Oncol.– 2004.– Vol. 15, N8.– P. 1173–1178.
41. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study / G. F. Fleming, V. L. Brunetto, D. Cella et al. // J. Clin. Oncol.– 2004.– Vol. 22, N11.– P. 2159–2166.
42. Randomized phase III noninferiority trial of first line chemotherapy for metastatic recurrent endometrial carcinoma: a Gynecologic Oncology Group study // D. Miller, V. Filiaci, G. Fleming et al. // Gynecol. Oncol.– 2012.– Vol. 125, N3.– P. 771.
Review
For citations:
Nechushkina V.M., Morkhov K.Yu., Kuznetsov V.V. . Malignant tumours. 2016;(4s1):92-98. (In Russ.)
Views:
947
Email this article 